Short answer
GRAIL, Inc. (GRAL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $38M (up 3.7% year over year) with net income of −$104M.
Q3 2026 key financials · XBRL
- Revenue
- $38M
- +3.7% YoY · −16.0% QoQ
- Net income
- −$104M
- −16.4% YoY · +6.1% QoQ
- Operating margin
- -385.3%
- EPS (diluted)
- −$1.98
- +19.2% YoY · +23.0% QoQ
Source: XBRL data from the GRAIL, Inc. (GRAL) Q3 2026 10-Q on SEC EDGAR. USD.
GRAIL, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $37.5M, up $1.3M YoY, driven by screening revenue $37.3M, up 14%
- Adjusted gross margin 42% vs 55% YoY, with screening cost ratio up approximately 11 percentage points
- Screening best performer: Galleri volume up 24%; development services revenue fell 92% to $0.1M
- Cash and securities $788.7M at September 30; operating cash used $242.5M versus $235.2M YoY
- Samsung financing generated $109.0M; FDA decision expected by early first quarter 2027, broader reimbursement remains unavailable
Risk Factors
- New securities litigation risk: June 2026 Robbins class action and Augitto derivative action allege misleading NHS-Galleri Trial disclosures
- New intellectual-property risk: September 2026 Clinical Genomics lawsuit alleges Galleri infringes two U.S. patents
- FDA approval risk updated: September 2026 advisory panel supported Galleri, but FDA may delay, restrict, or deny PMA approval
- Pricing risk updated: September 2026 promotional reductions may increase demand while lowering average selling prices and margins
- Regulatory risk reduced: SEC investigation into Illumina’s GRAIL-related disclosures closed May 9, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GRAIL, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.